<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2013</study_start_year><condition>Neoplasm Metastasis</condition><condition>Colorectal Neoplasms</condition><disease>Neoplasm Metastasis</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2153900</full_dataset_link><location>China</location><study_start_month>10</study_start_month><keyword>Chemotherapy</keyword><keyword>Liver metastasis</keyword><keyword>Avastin</keyword><keyword>Bevacizumab</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases</name><description>In this study, the investigators assessed the effect of avastin in combination with chemotherapy in the treatment of RAS mutant-type, unresectable colorectal liver-limited metastases</description><dates><creation>2013-10-15</creation></dates><accession>2153900</accession><cross_references><ClinicalTrials___gov>NCT01972490</ClinicalTrials___gov></cross_references></HashMap>